MYX 0.66% $4.60 mayne pharma group limited

you can't just compare an "asset" such as Metrics with a "drug"...

  1. 7,123 Posts.
    lightbulb Created with Sketch. 546
    you can't just compare an "asset" such as Metrics with a "drug" with highly un-predicable outlook and, potentially, out of control of MYX, they are simply different asset class.
    The similar deals in the past for MYX had all proven unsuccessful, what can guaranteed this time will be cash flow positive?
 
watchlist Created with Sketch. Add MYX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.